{"disease":{"id":"treatment-of-adult-patients-with-endocrine-resistant-pik3ca-mutated-hr-positive-her2-negative-locally-advanced-or-metastatic-breast-cancer-as-detected-by-an-fda-approved-test-following-recurrence-on-or-after-completing-adjuvant-endocrine-therapy-in-combination-with-inavolisib-and-fulvestrant.md","name":"treatment of adult patients with endocrine resistant pik3ca mutated hr positive her2 negative locally advanced or metastatic breast cancer as detected by an fda approved test following recurrence on or after completing adjuvant endocrine therapy in combination with inavolisib and fulvestrant.md"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}